The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its
carbohydrate content, results in a biologic profile with lower binding affinity, longer …

Background: CERA, a continuous erythropoietin receptor activator, is in development to
provide anemia correction and stable maintenance of hemoglobin (Hb) levels at extended …

Erythropoietin is the major hormone regulator of erythrocyte production promoting the
survival, as well as the differentiation and maturation, of erythroid progenitor cells. In …

Aim: This study was designed to assess the potential of the continuous erythropoietin
receptor activator (CERA) to correct anemia at extended administration intervals in …

The recombinant human erythropoietins epoetins alfa and beta have relatively short half-
lives (∼ 24 h by subcutaneous route) and have traditionally been administered 2 or 3 times …

The morbidity, mortality and economic burden of chronic kidney disease (CKD) and
associated anaemia are substantial. With the increasing numbers of patients who are likely …

Nearly three decades ago, recombinant human erythropoietin (EPO) transformed the
management of chronic kidney disease anemia by allowing a more sustained increase in …